Medication info
Sitafomin XR Controlled-release Tablet 50/1000 mg

Sitafomin XR Controlled-release Tablet 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Daehan New Pharm Co., Ltd.
Appearance
Bright green, oval-shaped controlled-release film-coated tablet with convex sides
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202202024 · Approved 2022.05.13 · Insurance code 669908270

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. The 100/1000 mg extended-release tablet of this drug is taken once daily as 1 tablet per dose. Patients taking the 50/500 mg or 50/1000 mg extended-release tablet of this drug take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no prior experience with antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug. 2. Patients receiving metformin treatment: - The recommended initial total daily dose of this drug for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start with their current doses of sitagliptin and metformin. - Patients who were receiving immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug, 50/1000 mg extended-release, once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment with this drug should not be initiated. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this drug must be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because of its metformin component.

Ingredients

Manufacturer
Daehan New Pharm Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is an adjunct to diet and exercise for improving blood sugar control in patients with type 2 diabetes. Sitagliptin and Metformin work together to effectively lower blood glucose levels, allowing for better glycemic management. When used alongside regular intake and proper lifestyle changes, this medication is expected to have positive effects on blood sugar control.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. The 100/1000 mg extended-release tablet of this drug is taken once daily as 1 tablet per dose. Patients taking the 50/500 mg or 50/1000 mg extended-release tablet of this drug take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no prior experience with antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug. 2. Patients receiving metformin treatment: - The recommended initial total daily dose of this drug for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start with their current doses of sitagliptin and metformin. - Patients who were receiving immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug, 50/1000 mg extended-release, once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment with this drug should not be initiated. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this drug must be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because of its metformin component.

Precautions

This medication contains two components: Sitagliptin and Metformin. Firstly, Sitagliptin helps to control blood sugar; however, it can occasionally cause serious allergic reactions or skin conditions, as well as pancreatitis, so symptoms should be closely monitored during use. Metformin is effective in lowering blood sugar, but it can be hazardous for patients with compromised kidney or liver function, potentially leading to a life-threatening condition known as lactic acidosis in severe cases. Therefore, this medication should not be administered to patients with moderate or severe renal impairment, acute heart failure, severe infections, dehydration, pregnant or breastfeeding women. Moreover, excessive alcohol consumption increases the risk of lactic acidosis, so alcohol should be avoided during treatment with this medication. During the course of taking this medication, regular kidney function and blood tests should be performed to monitor for abnormalities, and caution should be taken when experiencing irregular meals, intense exercise, or taking other medications, as there is a risk of hypoglycemia. If sudden respiratory difficulties, skin rash, swelling, severe abdominal pain, vomiting, or lethargy occur while taking this medication, immediate consultation with a doctor is recommended. If surgery is planned, this medication should be discontinued 48 hours beforehand and should not be resumed until kidney function has been confirmed as normal after the surgery. The safety and efficacy of this medication have not been established in children, and elderly patients should use it cautiously due to the risk of side effects associated with decreased kidney function. Hypoglycemic symptoms may occur, so especially when taken in combination with insulin or sulfonylureas, blood glucose levels should be monitored frequently, and symptoms should be carefully observed.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
Show 19 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • rash
  • urticaria
  • cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air and moisture infiltration. It is recommended to maintain a storage temperature between 1°C and 30°C to preserve the drug's efficacy over time.

Appearance and packaging

Appearance

Bright green, oval-shaped controlled-release film-coated tablet with convex sides

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.